- Home
- YORW vs PRTA Comparison
YORW vs PRTA Comparison
Compare YORW & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YORW | PRTA |
|---|---|---|
| Founded | 1816 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 495.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | YORW | PRTA |
|---|---|---|
| Price | $32.44 | $9.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 84.7K | ★ 787.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $76,882,000.00 | $11,786,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $7.69 | $819.08 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $29.68 | $4.32 |
| 52 Week High | $36.48 | $16.67 |
Technical Indicators
Market Signals| Indicator | YORW | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 42.93 |
| Support Level | $33.11 | $9.23 |
| Resistance Level | $32.99 | $9.88 |
| Average True Range (ATR) | 0.60 | 0.51 |
| MACD | -0.13 | -0.07 |
| Stochastic Oscillator | 4.21 | 19.51 |
Price Performance
Historical ComparisonAbout YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.